Shenzhen Weiguang Biological Faces Evaluation Shift Amid Bearish Technical Indicators

Shenzhen Weiguang Biological Products Co., Ltd., a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an adjustment in evaluation. This revision reflects a shift in the stock's technical indicators, which have shown a bearish trend. The technical analysis reveals that the MACD is currently bearish on a weekly basis, while it has shown mild bullishness on a monthly scale. The Bollinger Bands indicate a bearish stance for both weekly and monthly periods. Additionally, the KST presents a mildly bearish outlook weekly, contrasting with its mildly bullish monthly perspective. Financial metrics from the recent quarter ending September 2025 highlight challenges, with operating cash flow recorded at CNY 184.77 million, marking a low point. The return on capital employed (ROCE) stands at 10.24%, and net sales for the quarter have decreased to CNY 270.39 million, reflecting a decline of 18.36%. Over the past five years, net sales have grown at an annual rate of 4.95%, while operating profit has increased at 7.14%. Overall, the stock's performance has been below par, with negative returns of 9.51% over the last year, and it has underperformed relative to the China Shanghai Composite index across various time frames. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.